MTOR and cancer: ALK has also been described as rearranged or mutated in other cancer types [5, 7] and, in all the cases, its deregulated kinase activity leads to the activation of several downstream pathways such as MEK/ERK, STATs and AKT/mTOR, which result in abnormal proliferation and block of apoptosis.